Table 1.
Ongoing clinical studies implicating valproic acid in monotherapies.
| Dependences |
|---|
| Alcohol abuse or dependence |
| Alcoholism |
| Cocaine dependence |
| Marijuana abuse |
| Substance abuse or dependence |
| Substance withdrawal syndrome |
| Cancer |
| Autoimmune lymphoproliferative syndrome |
| Brain and central nervous system tumor |
| Breast cancer |
| CLL |
| HTLV-I associated myelopathy |
| MDS risk; AML |
| Nasopharyngeal carcinoma |
| Prostate cancer |
| Sarcoma |
| Neurological disorders |
| Alzheimer disease |
| Amyotrophic lateral sclerosis |
| Attention deficit hyperactivity disorder |
| Autism |
| Bipolar disorder |
| Borderline personality disorder |
| Cluster headache |
| Dementia |
| Depression |
| Disruptive behavior |
| Epilepsy |
| Mania |
| Migraine |
| Mood disorder |
| Neuralgia |
| Phosphosensitive epilepsy |
| Post traumatic stress disorder |
| Progessive supranuclear palsy |
| Resistant bipolar depression |
| Schizophrenia |
| Spinal muscular atrophy type 1 |
| Others |
| Asthma |
| Hypersplenism; lymphadenopathy |
| Hypoalbunemia |
| Insulin resistance |